Net loss in FY25 narrowed to $26.9 million from $30.9 million a year ago, with R&D costs falling to $16 million. ・Phase 3 ...

Both SLS009 and Galinpepimut-S are designed to address different stages of acute myeloid leukemia. ・Alliance Global said the updates on SLS009 and GPS strengthen the investment thesis for the ...

SELLAS Life Sciences Group (SLS) has drawn attention after a recent run in its share price, with returns over the past 3 ...

A late-stage clinical biopharmaceutical company focused on immunotherapy for various cancers, SELLAS Life Sciences Group ...

SELLAS Life Sciences Group (SLS) is back in focus after encouraging clinical updates on its leukemia programs, including Phase 2 data for SLS009 and ongoing progress in the Phase 3 REGAL trial for ...

$SLS insiders have traded $SLS stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales. Here’s a ...

NOSTRAND ROBERT L VAN, a director at $SLS, bought 10,000 shares of the company on 06-12-2025 for an estimated $14,800. This trade was reported by Quiver Quantitative ...